AGWCA
PCRX icon

Annis Gardner Whiting Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$91 – 988
2026
Q1 		$91 Buy
+4
New +$89 ﹤0.01% 1292
2025
Q3 		– Sell
-8
Closed -$192 – 1375
2025
Q2 		$192 Buy
+8
New +$202 ﹤0.01% 1291

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's PCRX Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 4 shares — an estimated $91 sold.

Annis Gardner Whiting Capital Advisors first reported a position in PCRX in Q2 2025 and held it in 2 quarters. The position peaked at $192 in Q2 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 4 Pacira BioSciences shares in Q2 2026, an estimated $91.
  • Annis Gardner Whiting Capital Advisors first reported a position in Pacira BioSciences in Q2 2025 and held it in 2 quarters.
  • Annis Gardner Whiting Capital Advisors's Pacira BioSciences position peaked at $192 in Q2 2025.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.